University of Utah researcher makes TIME100 list

What they're saying: Sundquist and Cihlar "have labored for more than a dozen years to turn one antiviral treatment, lenacapavir, into a twice-a-year therapy to prevent HIV infection in those at high risk," according to the magazine.

What we're watching: If the drug is approved for broad use, according to Time, it would be the first injectable treatment of its kind to prevent HIV and carries the potential to reduce infection rates.